Bridgefront Capital, LLC Allogene Therapeutics, Inc. Transaction History

Bridgefront Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.53 - $6.74 $130,219 - $193,748	-28,746 Reduced 72.72%	10,781 $53,000
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $194,472 - $324,516	39,527 New	39,527 $195,000
Q3 2022 Nov 29, 2022	BUY	$10.32 - $17.28 $211,683 - $354,447	20,512 New	20,512 $222,000
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $378,339 - $572,423	-14,670 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$25.24 - $43.45 $370,270 - $637,411	14,670 New	14,670 $370,000

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $240M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.